產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
- 400-999-210024小時(shí)服務(wù)熱線
NCI-H295R (人腎上腺皮質(zhì)腺癌細(xì)胞) (STR鑒定正確)
貨號:CL-0399
規(guī)格:1×10?cells/T25培養(yǎng)瓶
價(jià)格: ¥1600
生長培養(yǎng)基:DMEM/F12+0.5% ITS-G(100×)+10% FBS+1% P/S
產(chǎn)品概述
名稱 | NCI-H295R (人腎上腺皮質(zhì)腺癌細(xì)胞) (STR鑒定正確) |
別稱 | NCI H295R; NCIH295R; H295R; H-295R; H295R-S1 |
種屬 | 人 |
生長特性 | 貼壁細(xì)胞 |
細(xì)胞形態(tài) | 上皮細(xì)胞樣 |
凍存條件 | 凍存液:55% 基礎(chǔ)培養(yǎng)基+40%FBS+5%DMSO 溫度:液氮 |
培養(yǎng)方案A(默認(rèn)) |
生長培養(yǎng)基:
培養(yǎng)條件:
氣相:空氣,95%;CO2,5%, 溫度:37℃
|
推薦傳代比例 | 1:2-1:4 |
推薦換液頻率 | 2-3次/周 |
背景描述 | NCI-H295R細(xì)胞是源于多能腎上腺皮質(zhì)癌細(xì)胞系NCI-H295細(xì)胞,后者由Gazdar·A·F等建立,從腎上腺皮質(zhì)的腫瘤中分離而來。NCI-H295細(xì)胞經(jīng)改變培養(yǎng)條件獲得了NCI-295R細(xì)胞,群體倍增時(shí)間從原來的5天減為2天。NCI-295細(xì)胞懸浮生長,而NCI-H295R細(xì)胞呈單層貼壁生長。NCI-H295R細(xì)胞保留了產(chǎn)生雄激素的能力,對血管緊張素Ⅱ和鉀離子有反應(yīng)。 |
年齡(性別) | 女性;48歲 |
組織來源 | 器官:腎上腺 |
細(xì)胞類型 | 腫瘤細(xì)胞 |
腫瘤類型 | 腎上腺皮質(zhì)癌細(xì)胞 |
生物安全等級 | BSL-1 |
基因表達(dá)情況 | aldosterone; cortisol; C19 steroids |
保藏機(jī)構(gòu) | ATCC; CRL-2128 |
STR鑒定
-
STR位點(diǎn)信息
Amelogenin X CSF1PO 10,12 D2S1338 25 D3S1358 15,16 D5S818 12 D7S820 9,12 D8S1179 13 D13S317 13 D16S539 11 D18S51 17 D19S433 13 D21S11 32.2 FGA 19.2,24 PentaD 8 PentaE 5,12 TH01 9.3 TPOX 8 vWA 17,18 D6S1043 11 D12S391 19,20 D2S441 11 -
STR鑒定圖
參考文獻(xiàn)
-
Sinapine Targeting PLCβ3 EF Hands Disrupts Gαq-PLCβ3 Interaction and Ameliorates Cardiovascular Diseases(2023/11/15)
作者:Simeng Chu, Fukui Shen, Wenjuan Liu
期刊:PHYTOMEDICINE
DOI:10.1016/j.phymed.2023.155200
影響因子 :7.900
引用產(chǎn)品:CL-0399
-
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis(2022/10/02)
作者:Liwen Ren, Yihui Yang, Wan Li
期刊:Journal of Translational Medicine
DOI:10.1186/s12967-022-03641-y
影響因子 :7.400
-
Spatial lipidomics and metabolomics of multicellular tumor spheroids using MALDI-2 and trapped ion mobility imaging(2023/06/20)
作者:Jing Chen, Peisi Xie, Qingyuan Dai
期刊:TALANTA
DOI:10.1016/j.talanta.2023.124795
影響因子 :6.100
引用產(chǎn)品:CL-0399
-
N7-methylguanosine regulatory genes well represented by METTL1 define vastly different prognostic, immune and therapy landscapes in adrenocortical carcinoma(2023/02/15)
作者:Fangshi Xu, Danrui Cai, Shanshan Liu
期刊:American Journal of Cancer Research
DOI:PMID:36895966
影響因子 :5.300
引用產(chǎn)品:CL-0399
-
Identification of Seven Aberrantly Methylated and Expressed Genes in Adrenocortical Carcinoma(2019/07/12)
作者:He Xiao, Weixiang He, Ping Chen
期刊:Frontiers in Endocrinology
影響因子 :5.200
-
IFNγ enhances ferroptosis by increasing JAK?STAT pathway activation to suppress SLCA711 expression in adrenocortical carcinoma(2022/03/23)
作者:Xinbo Yu, Dandan Zhu, Bixian Luo
期刊:Oncology Reports
影響因子 :4.200
-
Combining virtual screening and in vitro evaluation for the discovery of potential CYP11B2 inhibitors(2022/08/01)
作者:Jiali Li, Na Yu, Hongmei Guo
期刊:Future Medicinal Chemistry
影響因子 :4.200
-
KIF11 is a potential prognostic biomarker and therapeutic target for adrenocortical carcinoma(2023/03/20)
作者:Yan Zhou, Xiang Chen, Bingsheng Li
期刊:Translational Andrology and Urology
影響因子 :2.000
FAQs
Q:{{item.question}}
A:
產(chǎn)品資料
識(shí)別碼示意圖